BioNexus Gene Lab Corp (NASDAQ: BGLC)

BioNexus Gene Lab Corp, also known as BGLC, operates in the chemical and diagnostic industries, with a focus on the Southeast Asia region. The company has two main segments: Chemical Raw Material Business and mRNA Diagnostics Business.

BioNexus' Chemical Raw Material Business is carried out through its subsidiary, Chemrex. Chemrex purchases raw chemical materials from domestic and international manufacturers and sells them to manufacturers in Southeast Asia. The company's products are used to produce a wide range of goods, including handrails, bench tops, automotive and aero parts, cleanroom panels, and covers for various instruments used in manufacturing. Chemrex's products are highly sought after due to their unique properties, such as lightweight and high strength, rust-free nature, and resistance to aging.

The mRNA Diagnostics Business is carried out through MRNA Scientific, which develops and provides safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers linked to diseases. MRNA Scientific's non-invasive blood tests analyze changes in RNA to detect the potential risk of 11 different diseases, including cancers, inflammatory bowel diseases, and osteoarthritis. The company's proprietary algorithm software, biomarkers, and RNA extraction, preservation, quality control, hybridization, and data analysis processes are key to its diagnostic capabilities.

BioNexus' growth strategy includes developing automated warehousing and logistics powered by artificial intelligence to guide its inventory control/movement and business decisions in a more streamlined and efficient manner. The company also intends to deepen its ties with its major business partners, hire more young and talented professionals to open more domestic and foreign markets, and constantly seek new products through various channels to add to its product line and expand its customer base.

The company's revenue is generated from the sale of chemical raw materials and mRNA diagnostics services. The company's primary products include chemical raw materials, such as lightweight and high-strength materials, rust-free materials, and materials resistant to aging. The company's primary services include mRNA diagnostics, which involve the development and provision of safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers linked to diseases.

In terms of its competitive position, BioNexus' mRNA Diagnostics Business is the only commercial molecular lab in Malaysia that detects cancer, inflammatory bowel diseases, and osteoarthritis risk via RNA with a certified GeneChip from the Food and Drug Administration (FDA). The company's competitive advantages include its technical expertise, pricing advantage, convenience, and sourcing new raw materials for product development.

BioNexus works with a range of customers, including manufacturers in Southeast Asia, healthcare providers, and research institutions. The company's products are used in various industries, including industrial, medical, appliance, aero, automotive, mechanical, and electronic industries.